Benzyl salicylate is a floral-balsamic aromatic ester widely used in fragrance and cosmetic systems and also found naturally in ylang-ylang, carnation, and tuberose-type materials. Its public evidence base is strongest for identity, cosmetic exposure, skin-sensitization review, and endocrine-screening debate rather than for consumer-facing wellness claims. For AromaForge, it is best framed as a common fragrance ester with clear floral relevance, low dermal penetration in one human-epidermis study, and safety language that should stay conservative around irritation and sensitization.
Chemical identity and composition
Benzyl salicylate has formula C14H12O3 and is the ester of benzyl alcohol and salicylic acid. The CIR review describes it as a colorless to pale yellow liquid with low water solubility and documents both fragrance use and light-stabilizer use in cosmetics.
Aroma and practical use
- Use the recorded floral, jasmine-like, balsamic, sweet, mushroom-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The CIR safety assessment reports that benzyl salicylate penetrated human epidermis very slightly, with 0.031% plus or minus 0.004% of the applied amount traversing the skin in one in vitro study.
That low-permeation result is one reason the CIR panel treated endocrine-screening signals as less relevant to real-world cosmetic exposure.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The same CIR review summarizes in vitro estrogen-responsive cell data showing increased MCF-7 proliferation at 10-4 M and 10-5 M in some assays, alongside discussion that low dermal absorption would limit systemic exposure in cosmetic use.
This is a useful example of mixed evidence: a real mechanistic signal exists, but the exposure relevance is debated and limited.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2021 critical assessment concluded that benzyl salicylate is a partial agonist with 35-47% maximal efficacy and becomes active only close to cytotoxic concentrations.
That paper narrows the interpretation of endocrine concern and is more precise than simply labeling the constituent estrogenic.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Case and patch-test literature documents sensitization in some patients, including older reports of intensified contact sensitization during topical psoralen therapy.
This supports conservative allergy wording without implying that sensitization is universal or high-frequency.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedCIR concluded benzyl salicylate is safe in present cosmetic practices when products are formulated to be non-irritating and non-sensitizing.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
IFRA restrictions and EU fragrance-allergen labeling requirements reflect real sensitization-management concerns.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Open evidence for endocrine activity is mixed and mainly assay-based; archive language should avoid oversimplifying this into a direct human hazard claim.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
very slight penetration through human epidermis in one in vitro model
The CIR review reports that only about 0.031% of applied benzyl salicylate traversed human epidermis in a 72-hour glass-chamber experiment.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
estrogen-receptor related activity in screening assays
CIR and a later critical assessment both describe partial estrogenic agonist-type signals in vitro, but only near concentrations that overlap with cytotoxicity or under exposure assumptions judged not systemically relevant for cosmetic use.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- This pass did not verify robust human clinical literature focused on isolated benzyl salicylate beyond safety and sensitization contexts.
- The public record is much stronger for exposure and risk assessment than for beneficial constituent-specific effects.
- Endocrine-screening results remain interpretation-sensitive and should not be converted into direct human outcome claims.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.